科研之友
微信
新浪微博
Facebook
分享链接
摘要
Estrogen and estrogen receptor (ER)-alpha and -beta play a role in the development and progression of thyroid cancer. ER beta 2 is one major splicing variant of ER beta. In this study, we investigated the clinical significance of ER beta 2 protein expression in the papillary thyroid carcinoma (PTC) lesion. ER beta 2 expression was immunohisto-chemically examined in formalin-fixed, paraffin-embedded thyroid tissues from 106 patients with PTC by Elivision (TM) plus two-step system as previously described. The relationships between ER beta 2 expression and clinicopathological/biological factors were then analyzed. ER beta 2 protein was expressed in all the PTC patients studied. It was positively associated with Ki-67 expression in female PTC patients with advanced reproductive age (>45 years, in low-estrogen status) and with VEGF expression in male PTC patients with reproductive age (18 similar to 45 years, in low-estrogen status) (P=0.005 and P=0.044, respectively). There was no association between ER beta 2 expression and tumor size, extrathyroidal extension and tumor-node-metastasis stage in PTC patients. In addition, ER beta 2 expression was lower in female patients of reproductive age (18 similar to 45 years, in relatively high-estrogen status) with lymph node metastasis than that in those patients without lymph node metastasis (P=0.035). The present results suggest that the expression of ER beta 2 in PTC is associated with the progression of the disease. Its potential effect may vary with different estrogen status. Further study will assess the underlying molecular mechanisms of ER beta 2 in PTC.
- 出版日期2015
- 单位中国医科大学
